Sarepta Therapeutics preclinical data

In non-human primates infected with Marburg virus, once-daily 7.5-30 mg/kg doses of intramuscular AVI-7288 given 1 hour post-infection and for 13 subsequent days produced 83-100% survival rates over a 40-day evaluation period vs. 0% for placebo. Last year, Sarepta reported that IV AVI-7288 given up to 4 days post-infection produced similar survival rates in non-human primates to that of the intramuscular formulation (see BioCentury, July 30, 2012). Also last year, Sarepta completed a Phase I trial evaluating single ascending-doses of IV AVI-7288, which has Fast Track designation in the U.S. for the indication. ...